This clinical trial investigates the use of Xeomin (a type of botulinum toxin A) for people with chronic migraine. Chronic migraine is a condition where a person experiences headaches on 15 or more days per month, with at least 8 of these being migraine headaches, for more than 3 months. The study aims to determine if Xeomin injections are effective in reducing the number of days patients experience migraines compared to placebo.
The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.
During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.
Austria 
Czechia 
Denmark 
France 
Germany 
Italy 
Poland 
Slovakia 
Spain 